For patients diagnosed with advanced lung cancer driven by a specific genetic flaw called KRAS G12C, the first-line treatment playbook has relied on combining immunotherapy with platinum-based chemotherapy. That standard may be shifting. Integrated data from two clinical trials, presented at the IASLC World Conference on Lung Cancer and based on a January 15, 2025 data cutoff, showed that the oral KRAS inhibitor olomorasib paired with pembrolizumab produced objective response rates above 74 percent in previously untreated patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC). The drug’s developer, Eli Lilly and Company, has confirmed that a registration-enabling data readout from the ongoing SUNRAY-01 trial is expected at an upcoming ASCO presentation in 2026.
If those results hold, olomorasib would post the highest first-line response rate reported for any KRAS G12C-targeted combination to date, surpassing the roughly 63 percent objective response rate seen with adagrasib plus pembrolizumab in the KRYSTAL-7 trial and far exceeding historical benchmarks for chemotherapy-immunotherapy regimens, which typically produce responses in 40 to 50 percent of unselected NSCLC patients. About 13 percent of lung adenocarcinomas harbor the KRAS G12C mutation, according to genomic profiling studies published in Nature Reviews Clinical Oncology, making this one of the most common actionable targets in the disease.
Two trials built the case
The clinical evidence behind olomorasib rests on two studies running in sequence. The first, LOXO-RAS-20001 (NCT04956640), is a first-in-human dose-escalation study that tested olomorasib as a single agent across multiple KRAS G12C-mutant solid tumor types. Investigators used that trial to identify the recommended phase 2 dose, characterize pharmacokinetics, and document early antitumor activity in heavily pretreated patients. A peer-reviewed report on the monotherapy results, published in Nature Communications, confirmed on-target KRAS G12C inhibition and measurable tumor shrinkage with a tolerability profile that supported combining the drug with other agents.
Those findings opened the door to SUNRAY-01 (NCT06119581), a randomized, placebo-controlled phase 3 trial that represents the pivotal bet. SUNRAY-01 enrolls adults with previously untreated, metastatic KRAS G12C-mutant NSCLC confirmed by central testing. Patients are randomized to receive either olomorasib or placebo alongside a pembrolizumab-based backbone. The trial stratifies enrollment by PD-L1 expression, a protein marker that helps predict how well a patient’s tumor will respond to checkpoint immunotherapy, ensuring that patients with high and low PD-L1 levels are evenly distributed across treatment arms.
Critically, SUNRAY-01 also includes a comparison structure designed to answer whether adding platinum-based chemotherapy to the olomorasib-pembrolizumab combination provides additional benefit. Some patients receive a two-drug oral-plus-immunotherapy regimen; others receive a three-drug combination that layers in intravenous chemotherapy. For patients, the practical difference is significant: fewer infusion visits, less cumulative toxicity, and a potentially better quality of life if the chemotherapy-free arm proves equally effective. The published trial protocol details the eligibility criteria, PD-L1 stratification thresholds, and planned endpoints for response, progression-free survival, and overall survival.
The integrated analysis combining first-line patients from both LOXO-RAS-20001 and SUNRAY-01 was presented as abstract MA02.06 at WCLC 2025. That presentation produced the headline figure: an objective response rate exceeding 74 percent for olomorasib plus pembrolizumab in the frontline setting.
Where olomorasib fits in a crowded KRAS race
Olomorasib is not the first KRAS G12C inhibitor to reach patients. Amgen’s sotorasib (Lumakras) received accelerated FDA approval in 2021 for previously treated KRAS G12C-mutant NSCLC, and Bristol Myers Squibb’s adagrasib (Krazati) followed in 2022 for the same second-line indication. Both drugs validated the target but posted modest single-agent response rates in the range of 28 to 43 percent, and neither has yet secured a first-line approval based on a randomized trial.
The competitive landscape shifted when investigators began combining KRAS G12C inhibitors with pembrolizumab. Adagrasib plus pembrolizumab in the KRYSTAL-7 trial reported a first-line ORR of approximately 63 percent, a meaningful jump over monotherapy but one that came with notable rates of immune-related adverse events. Sotorasib’s combination with pembrolizumab was complicated by liver toxicity signals in early studies, prompting Amgen to pursue alternative combination strategies.
Against that backdrop, olomorasib’s reported response rate above 74 percent stands out. But response rate alone does not determine clinical superiority. What oncologists and regulators need to see next is whether those responses translate into longer progression-free survival and overall survival compared with the current standard of pembrolizumab plus platinum-based chemotherapy. That is precisely what the SUNRAY-01 pivotal readout is designed to deliver.
What the data do not yet show
Several pieces of the puzzle remain missing from the public record as of June 2026. The 74 percent-plus response rate comes from a conference abstract, which by nature compresses complex datasets into summary statistics. Detailed confidence intervals, response duration broken down by PD-L1 subgroup, and waterfall plots showing depth of individual tumor shrinkage have not appeared in a peer-reviewed publication or regulatory filing.
That subgroup question is not academic. If olomorasib’s benefit is concentrated in patients with high PD-L1 expression, who already respond relatively well to pembrolizumab alone, the drug’s added value narrows. If the KRAS inhibitor lifts response rates most sharply in patients with low or absent PD-L1, where immunotherapy historically underperforms, olomorasib could redefine the standard of care for the hardest-to-treat segment of this population.
Safety data from the combination arms also remain incomplete in the public domain. The monotherapy paper from LOXO-RAS-20001 documents adverse events including gastrointestinal symptoms and laboratory abnormalities, but the toxicity profile of olomorasib combined with pembrolizumab, and especially the three-drug regimen with added chemotherapy, has been described only in summary form. Full safety tables covering immune-related adverse events, overlapping toxicities, and treatment discontinuation rates have not been published.
Perhaps most importantly, progression-free survival and overall survival data have not been publicly reported. The SUNRAY-01 protocol outlines the statistical framework for these endpoints, including planned interim analyses and significance thresholds, but the actual observed survival curves remain under wraps pending the pivotal readout. Historically, some targeted therapies have produced striking initial response rates that did not translate into proportionate survival gains once resistance mechanisms, treatment crossover, and subsequent therapies were factored in. Others have delivered durable benefits that reshaped treatment guidelines. Where olomorasib lands on that spectrum will determine its ultimate impact.
Why resistance biology looms over every KRAS inhibitor
One question that clinicians and researchers are already asking is how long olomorasib can keep KRAS G12C-mutant tumors in check. All three approved or late-stage KRAS G12C inhibitors, including sotorasib and adagrasib, face acquired resistance driven by secondary KRAS mutations, bypass pathway activation through genes like MET and EGFR, and histologic transformation. Published resistance profiling from the CodeBreaK and KRYSTAL programs has shown that tumors can reactivate RAS signaling through multiple escape routes, sometimes within months of initial response.
Whether olomorasib’s binding characteristics or pharmacokinetic profile offer any advantage in delaying resistance is not yet clear from public data. The SUNRAY-01 trial includes translational endpoints that may shed light on resistance patterns, but those analyses are unlikely to be available until well after the primary efficacy readout. For now, the assumption should be that olomorasib will face similar biological headwinds, and that the durability of its responses will be a critical variable in determining its clinical value.
What the ASCO readout needs to deliver
The upcoming ASCO presentation carries enormous weight. For olomorasib to move from promising candidate to new standard of care, the pivotal data will need to show not just a high response rate but a statistically significant improvement in progression-free survival over the control arm. Regulators at the FDA and EMA will scrutinize the hazard ratios, the consistency of benefit across PD-L1 subgroups, and the safety profile of the combination in a larger, more diverse patient population than the early-phase cohorts.
Eli Lilly has invested heavily in the KRAS franchise, and a positive SUNRAY-01 readout would position olomorasib as a potential first-in-class first-line KRAS G12C therapy. For the roughly 30,000 patients diagnosed annually in the United States with KRAS-mutant NSCLC, and the subset of those carrying the G12C variant, the stakes are personal. A regimen that pairs an oral targeted pill with immunotherapy and potentially eliminates the need for intravenous chemotherapy would represent a genuine change in how treatment feels, not just how it performs on a scan.
The verified evidence through June 2026 supports real optimism: a well-designed randomized trial, a response rate that outpaces anything previously reported for this mutation, and a regulatory path that is clearly accelerating. What it does not yet support is certainty. The survival data, the subgroup analyses, and the full safety accounting will fill in the gaps. Until then, olomorasib sits at the threshold between a compelling early signal and a proven advance, and the next few months will determine which side of that line it falls on.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
